The Application of Locoregional Therapy Combined With Systemic Therapy in the Perioperative Perio… (NCT07639294) | Clinical Trial Compass
CompletedNot Applicable
The Application of Locoregional Therapy Combined With Systemic Therapy in the Perioperative Period of Huge Hepatocellular Carcinoma: A Retrospective Cohort Study
China715 participantsStarted 2018-06-01
Plain-language summary
This retrospective cohort study collected data of patients with huge hepatocellular carcinoma (HCC) treated between June 1, 2018, and December 31, 2023, through the hospital information system. Patients were divided into a neoadjuvant conversion-first cohort and an upfront surgery cohort based on whether they received preoperative locoregional therapy combined with targeted and immunotherapy. The conversion-first cohort was further stratified into a conversion surgery group and a non-surgery group according to whether curative-intent hepatectomy was ultimately achieved. The upfront surgery cohort was divided into a postoperative adjuvant therapy group and a postoperative surveillance group based on whether adjuvant immunotherapy was administered after surgery. The primary objective was to analyze differences in overall survival (OS) and progression-free survival (PFS) among the four groups and to evaluate the impact of neoadjuvant conversion therapy on the safety of hepatectomy.
Who can participate
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* pathologically or clinically diagnosed HCC with a tumor diameter exceeding 10 cm on initial computed tomography (CT) or magnetic resonance imaging (MRI);
* ≤ 3 tumor nodules;
* portal vein tumor thrombus (PVTT) that had not invaded the main portal vein or the contralateral branch of portal vein (Vp0-3 PVTT);
* absence of extrahepatic metastasis; (5) Child-Pugh score of 5-7 and Eastern Cooperative Oncology Group performance status of 0-1.
Exclusion Criteria:
* mixed tumors with HCC and cholangiocarcinoma;
* recurrent HCC;
* tumor thrombus invading the inferior vena cava;
* combined with any malignancy other than HCC;
* incomplete clinical or follow-up data.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
overall survival
Timeframe: From date of treatment until the date of death from any cause, assessed up to 66 months